![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![AbbVie Header](https://www.pharmacompass.com/image/flap/abbvie-header-w29-desktop-header-1gif-4289.gif)
![AbbVie Header](https://www.pharmacompass.com/image/flap/abbvie-header-w29-mobgif-81230.gif)
Active Filter(s):
Details:
Through the acquisition, Bora will utilize Almatica's generic pharmaceutical products, including Zestril (lisinopril), an oral tablet used for treating hypertension, for commercialization purposes.
Lead Product(s): Lisinopril
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Zestril
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: TWi Pharmaceuticals, Inc.
Deal Size: $38.5 million Upfront Cash: Undisclosed
Deal Type: Acquisition August 18, 2023